Anna Maria Ioppolo

Interventional Cardiologist | Humanitas Gavazzeni (Italy)

[Guillaume Bonnet @guilbon]

#PCRLV #PCRLV2023
Mitral Breaking Trial.
« The most important thing is to repair the leak, regardless of the gradient level !!!! »

🎯 In echo core lab-assessed outcomes from the EXPANDed studies, 90% of subjects achieved significant MR reduction to <1+ with 72% also maintaining a MVG <5 mmHg at 30 Days and experienced significant improvements in NYHA functional class.
🎯 Subjects with 30-day MVG 25 mmHg had a decrease in gradient at 1 year.
Subjects with 30-day MR 51+ had lower all-cause mortality than MR 22+,
🎯 Regardless of MV gradient, reduction of MR to mild or less was associated with 1-year improvements in functional capacity and lower risk of death

[Anna Maria Ioppolo @am_ioppolo]

#PCRLV 2023 opening ceremony

[EuroIntervention @EuroInterventio]

This article proposes a standardised approach to evaluate patients with TR who may be candidates for transcatheter interventions. Read more on the available transcatheter therapies, the main criteria for patient and device selection. #EIJBestOf @FabienPraz https://t.co/dGTO1gWjjD

[Felice Gragnano @FeliceGragnano]

Compared to IV #fentanyl, IV #acetaminophen was associated w/ significantly higher concentrations of ticagrelor after pPCI for STEMI and resulted in effective pain relief #EHJPharmacotherapy 💉⤵️
https://t.co/nnLUBqPwtb
@AgewallStefan @ESC_Journals @escardio
#CardioTwtitter

[Guillaume Bonnet @guilbon]

COAPT5Y : TEER in FMR durable, strong benefit !
🎯TEER safe, reduced HFHs, Mortality 5Y
🎯Across all subgroups (age, sex, MR severity, LVEF, volume, etiology, surgical risk)
🎯Durable repair
🎯Prognosis of crossover pts = similar with originally TEER pts
#ACC23 #WCCardio

[Anna Maria Ioppolo @am_ioppolo]

@DrRajeshG1 Chiari

[Benoy Shah MD @dr_benoy_n_shah]

#ACC2023

Deep Dive on #TRILUMINATE

This was presented yesterday

Lots of discussion already

So I'll try not to repeat too much, but this is for anyone that hasn't read the paper yet &amp; wants a summary

#MedTwitter #cardiotwitter #echofirst #ACCFIT #EACVI

[Anna Maria Ioppolo @am_ioppolo]

@MatthewChungMD @DSteve37 A quick echo (echo-Fast) during patient preparation is crucial…it could give serveral informations: aortic dilation (or dissection), EF, mechanical complications and so on

[Anna Maria Ioppolo @am_ioppolo]

Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club via @EuroInterventio https://t.co/QW3rkYr6pc

[Davide Capodanno @DFCapodanno]

Myocardial hibernation results from chronic low flow or repetitive episodes of stunning with metabolic adaptation. The myocardium remains viable and recovery of function occurs in weeks to months after revascularization.

Then, the REVIVED trial.
https://t.co/mDYyKaV73P

[Anna Maria Ioppolo @am_ioppolo]

Very educational session about TAVI-in-TAVI at #PCRLV @PCRonline

[Jonathan Curio @CurioJonathan]

📍Worldwide first commercial experience w/ JenaValve Trilogy for #vhdAS &amp; #vhdAR presented by @MattiAdam_MD at #PCRLV

🎯95 pat (37 AS, 58 AS)
🎯100% VARC-3 tech success, 83% VARC-3 early safety
🎯90% none, 10% mild PAR; 18% PPI in AR needs more eval

@PCRonline @VictorMauriMD

[Anna Maria Ioppolo @am_ioppolo]

LuX valve and K-Clip for transcatheter treatment of severe tricuspid regurgitation #PCRLV #tricuspid #innovation @PCRonline

[Alessandro Sticchi @Sticchi_Alex]

Amazing result!! #PCRLV
@Dr_Harriet @PCRonline @dr_chrisallen @dromar_c @kiadeb87 @am_ioppolo

[Anna Maria Ioppolo @am_ioppolo]

Amazing session about state of the art of transcatheter intervention for mitral and tricuspid valve disease..live from #PCRLV @PCRonline @didier_tchetche @modine_thomas

[Victoria Delgado @VDelgadoGarcia]

#PCRLV today there were mitral and tricuspid tracks excellent cases, presentations and discussions @patmahia @AnnaSannino1985 @dralisonduncan @hahn_rt @FabienPraz @masitges @MadalinaGarbi @didier_tchetche @nicolasdumonte1

[EAPCIPresident @EAPCIPresident]

❓How do you treat Tricuspid Valve disease❓

Enjoy free access to this chapter on Transcatheter Tricuspid Valve Interventions from the PCR-#EAPCI Textbook until 1st December

@nbuzzatti @giuliorus @azeemlatib @drmaisano

🔗 https://t.co/vqmXg26O4M

[PCRonline 🫀 @PCRonline]

Join #PCRLV from your home on 27-29 November! Register for the online package 💻 to access 70+ sessions, exclusive content, and a live chat to stay connected with your community.

[PCRonline 🫀 @PCRonline]

🤩3,000+ peers are joining #PCRLV 2022! What about you? 🖥️ Online or 🇬🇧 on-site, come learn, share and network at the ❤️ Heart Team Course on 27-29 November!

[EuroIntervention @EuroInterventio]

This review aims to summarise literature data about coronary access after #TAVI and examine the underlying conditions that make coronary re-engagement more challenging or even impossible.#EIJBestOf https://t.co/gEeImu8zjq @RobertoValvo @barbanti_marco @tambucor